Roche immunotherapy Tecentriq gains European approval for breast cancer

Roche's Tecentriq has won European approval for use against a tough-to-treat breast cancer, helping the Swiss drugmaker to widen use of an immunotherapy that has so far been eclipsed in revenue terms by more-established rival medicines.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news